The company and its board of directors ensure that the information provided is true, accurate, complete, and free from false records or misleading statements.
Zhejiang Sali Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company") held its 15th (temporary) meeting of the 8th board of directors on May 29, 2026, and approved the "Announcement on Adjusting the Grant Price of the 2024 Restricted Stock Incentive Plan." The relevant matters are announced as follows:
- The relevant approval procedures for this incentive plan have been completed.
(1) On October 25, 2024, the Company held the 1st extraordinary general meeting of shareholders and approved the "2024 Restricted Stock Incentive Plan" (hereinafter referred to as "the Plan") and the "Proposal on the Implementation of the 2024 Restricted Stock Incentive Plan" and "Proposal on the Authorization of the Board of Directors to Handle Matters Related to the 2024 Restricted Stock Incentive Plan."